Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02575339 · ClinicalTrials.gov registry record · Phase 1
MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma
A Phase 1 study, sponsored by Kathy Miller.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02575339 is a Phase 1 study that was terminated before completion, run by Kathy Miller. The registered enrollment target is 11 participants.
The verdict
NCT02575339, a Phase 1 study, was terminated before completion, sponsored by Kathy Miller.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
This is an open label, multi-center, randomized phase I/II study of MLN0128 versus standard sorafenib. Eligible subjects in the phase I trial will receive MLN0128 in escalating doses. Eligible subjects in the phase II trial will be 1:1 randomized to either the MLN0128 arm or the sorafenib arm.
Interventions
- DRUG Sorafenib
- DRUG MLN0128
- DRUG MLN0128 (RP2D)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2016-07-18 |
| Est. Completion | 2020-11-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02575339
The ClinicalTrials.gov registry entry for NCT02575339 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kathy Miller, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Sorafenib is the first listed.
NCT02575339 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02575339 about?
NCT02575339 is a clinical study titled "MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma". This is an open label, multi-center, randomized phase I/II study of MLN0128 versus standard sorafenib. Eligible subjects in the phase I trial will receive MLN0128 in escalating doses. Eligible subjects in the phase II trial will be 1:1 randomized to either the MLN0128 arm or the sorafenib arm.
What is the current status of trial NCT02575339?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2016-07-18. Estimated completion is 2020-11-24.
What interventions are being tested in trial NCT02575339?
The interventions under investigation include: Sorafenib (DRUG), MLN0128 (DRUG), MLN0128 (RP2D) (DRUG).
Who is sponsoring clinical trial NCT02575339?
This trial is sponsored by Kathy Miller, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.